Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses how integrated delivery networks (IDNs) can help drive biosimilar adoption. Sophia Humphreys, ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

Number 5: By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous ...